Lin BioScience, Inc.
6696
शेयरों में रैंक
#3906
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
शेयर मूल्य
$5.03
मार्केट कैप
$4.17B
बदलाव (1 दिन)
-5.81%
बदलाव (1 वर्ष)
-44.72%
देश
TW
व्यापार Lin BioScience, Inc. (6696)
श्रेणी
Healthcare
Lin BioScience, Inc. (6696) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $5.40 (2026-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $1.30 (2018-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $1.30 (2018-10-01 को)
Lin BioScience, Inc. के स्टॉक मूल्य का इतिहास 2018 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2026 (TTM) | -4.14% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $534.12 | 25.25% |
US
|
|
| $231.12 | 760.78% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $880.75 | 8.18% |
NL
|
|
| $289.51 | 1.72% |
BE
|
